drugset / Trial / NCT01229111

Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers

NCT01229111

Phase 2 Terminated 14 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well giving cediranib maleate together with combination chemotherapy works in treating patients with advanced biliary cancers. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving cediranib maleate together with combination chemotherapy may kill more tumor cells.

Timeline

Start
2010-10
Primary completion
2014-03
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Cediranib Small molecule Oral
Subject Leucovorin Small molecule Intravenous
Subject Oxaliplatin Small molecule Intravenous
Subject fluorouracil Small molecule Intravenous